Archive · 29 Sep 2026
Moderna mRNA Flu Vaccine Shows Nearly 30% Better Protection
Scientists tested a new flu vaccine for adults aged 50 and older.
The vaccine is called MFLUSIVA.
It uses mRNA technology.
In a large Phase 3 study, it provided nearly 30% more protection than a standard-dose flu shot.
Moderna makes the vaccine.
The U.S. Food and Drug Administration approved it in August 2026.
It is meant to protect against flu strains included in the vaccine.
The approval applies to adults who are at least 50 years old.
Moderna’s MFLUSIVA showed nearly 30% better protection than a standard-dose flu vaccine in adults aged 50 and older.
The finding came from a large Phase 3 trial.
MFLUSIVA is an mRNA-based influenza vaccine made by Moderna.
The U.S. Food and Drug Administration approved MFLUSIVA in August 2026.
The vaccine is approved for adults 50 and older against influenza caused by strains included in the vaccine.
- Who
- Moderna developed MFLUSIVA, and the vaccine is intended for adults aged 50 and older.
- What
- A large Phase 3 trial found that the mRNA flu vaccine provided nearly 30% better protection than a standard-dose flu vaccine.
- When
- The U.S. Food and Drug Administration approved MFLUSIVA in August 2026; the article does not specify when the trial results were published.
- Where
- The vaccine was approved in the United States.
- Why
- It is intended to help prevent influenza caused by the virus strains included in the vaccine, with particular attention to adults aged 50 and older.
- Vaccine
- MFLUSIVA
- Manufacturer
- Moderna
- Technology
- mRNA-based influenza vaccine
- Trial
- Large Phase 3 trial
- Protection result
- Nearly 30% better protection than a standard-dose flu vaccine
- Approved age group
- Adults aged 50 and older
- Approval date
- August 2026
- Approving authority
- U.S. Food and Drug Administration